...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor alpha
【24h】

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor alpha

机译:奥拉帕拉巴通过抑制血小板衍生的生长因子受体α在小儿骨和软组织肿瘤中施加抗肿瘤活性

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Platelet-derived growth factor receptor alpha (PDGFR alpha) is implicated in several adult and pediatric malignancies, where activated signaling in tumor cells and/or cells within the microenvironment drive tumorigenesis and disease progression. Olaratumab (LY3012207/IMC-3G3) is a human mAb that exclusively binds to PDGFR alpha and recently received accelerated FDA approval and conditional EMA approval for treatment of advanced adult sarcoma patients in combination with doxorubicin. In this study, we investigated olaratumab in preclinical models of pediatric bone and soft tissue tumors.
机译:目的:血小板衍生的生长因子受体α(PDGFRα)涉及几种成人和儿科恶性肿瘤,其中在微环境驱动肿瘤瘤和疾病进展中肿瘤细胞和/或细胞中的活化信号传导。 Olaratumab(Ly3012207 / IMC-3G3)是一种人体mAb,它专门与PDGFR alpha结合,最近接受加速的FDA批准和有条件的EMA批准,用于治疗高级成人肉瘤患者与多柔比星组合治疗。 在这项研究中,我们在小儿骨和软组织肿瘤的临床前模型中研究了奥拉撒布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号